Home Tags Arkin Bio Capital

Arkin Bio Capital

Human Immunology Biosciences (HI-Bio™), a clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases (IMDs), announced the closing of a $95 million Series B financing led by new investor Alpha Wave Global. Viking Global Investors and Arkin Bio Capital participated in the financing, as well as existing investors Jeito Capital and ARCH Venture Partners.

[Funding alert]HI-Bio Raises $95 Mn Series B Funding to Advance Targeted...

Startuprise io -
© Copyright startuprise 2024 All Rights Reserved.
Exit mobile version